Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 10/04/2019)

1st line
IPSOS (Roche)
A phase III, open-label, multicenter, randomized study to investigate the efficacy and safety of atezolizumab compared with chemotherapy in patients with treatment-naïve advanced or recurrent (stage IIIB not amenable for multimodality treatment) or metastatic (stage IV) non-small cell lung cancer who are deemed unsuitable for platinum-containing therapy.

LUNG037 M7824 versus PEMBROLIZUMAB (Merck)
A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer.

2th line 
RO6874281 (Roche)
An open-label, multicentre, phase II study to evaluate the therapeutic activity of RO6874281, an immunocytokine, consisting of interleukin-2 variant (IL-2V) targeting fibroblast activation protein-A (FAP), in combination with atezolizumab (anti-PD-L1), administered intravenously, in participants with advanced and/or metastatic sold tumors (only cohort F).

CAPMATINIB / SPARTALIZUMAB (Novartis)
A phase II, multicenter, randomized, two-arm study of capmatinib (INC280, an oral MET inhibitor) and spartalizumab (PDR001, a PD-1 inhibitor) combination therapy versus docetaxel in pretreated adult patients with EGFR wild-type, ALK rearrangement negative locally advanced/metastatic non-small cell lung cancer (currently Run-in period).


3th line 
CAPMATINIB / SPARTALIZUMAB (Novartis)
A phase II, multicenter, randomized, two-arm study of capmatinib (INC280, an oral MET inhibitor) and spartalizumab (PDR001, a PD-1 inhibitor) combination therapy versus docetaxel in pretreated adult patients with EGFR wild-type, ALK rearrangement negative locally advanced/metastatic non-small cell lung cancer (currently Run-in period).

 

New trial in start-up: currently no new trials